BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada. Show more

Location: Bellevue Centre, West Vancouver, BC, V7T 2X1, Canada | Website: https://briacell.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

19.83M

52 Wk Range

$0.35 - $9.82

Previous Close

$2.91

Open

$2.29

Volume

6,646,073

Day Range

$2.05 - $2.36

Enterprise Value

6.987M

Cash

12.46M

Avg Qtr Burn

-6.018M

Insider Ownership

7.33%

Institutional Own.

10.88%

Qtr Updated

04/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Bria-IMT™ (SV-BR-1-GM) Details Breast cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bria-OTS™ + tislelizumab Details Breast cancer, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bria-PROS+ Details Cancer, Prostate cancer	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.